{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:21:03Z","timestamp":1792102863955,"version":"4.4.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current treatments for glaucoma to lower intraocular pressure (IOP) are dependent on patient adherence and bioavailability after bypassing ocular barriers. Our study investigated the safety and efficacy of a liposomal nanocarrier for sustained release of latanoprost injected into the suprachoroidal space in the rabbit eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dutch-Belt rabbits were injected with a single dose of 150\u202f\u03bcL of 2\u202fmg\/mL of liposomal latanoprost formulation into the suprachoroidal space. The eyes were clinically monitored for adverse events and the IOP recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IOP reduced from baseline to 8\u202fh post liposomal latanoprost injection by 28% (5.1\u202f\u00b1\u202f2.12\u202fmmHg), reaching a maximum of 40% (7.2\u202f\u00b1\u202f1.9\u202fmmHg) at Day 5. Low IOP was sustained until Day 56 returning to baseline at Day 90. Safety assessment of the eyes showed no adverse events and good tolerability of the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A single dose of liposomal latanoprost into the suprachoroidal space can lower the IOP for up to 56\u202fdays making it a promising therapeutic agent for sustained delivery drugs to the suprachoroidal space.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1776626","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:05Z","timestamp":1772775005000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit"],"prefix":"10.3389","volume":"13","author":[{"given":"Phey Feng","family":"Lo","sequence":"first","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]},{"name":"Singapore National Eye Centre","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Bo Bo","family":"Tun","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan E. K.","family":"Man","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]},{"name":"Singapore National Eye Centre","place":["Singapore, Singapore"]},{"name":"Duke-NUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Marie Fianza","family":"Busoy","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamira","family":"Perera","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]},{"name":"Singapore National Eye Centre","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veluchamy A.","family":"Barathi","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]},{"name":"Duke-NUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina T.","family":"Wong","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute","place":["Singapore, Singapore"]},{"name":"Singapore National Eye Centre","place":["Singapore, Singapore"]},{"name":"Duke-NUS Medical School","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e11686","DOI":"10.7759\/cureus.11686","article-title":"Epidemiology of Glaucoma: the past, present, and predictions for the future","volume":"12","author":"Allison","year":"2020","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archophthalmol.2010.345","article-title":"Persistence of patients receiving topical glaucoma monotherapy in an Asian population","volume":"129","author":"Quek","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1034\/j.1600-0420.2001.790604.x","article-title":"Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study","volume":"79","author":"Larsson","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","article-title":"Sustained-release drug delivery systems for the treatment of glaucoma","volume":"14","author":"Kesav","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"251584142090574","DOI":"10.1177\/2515841420905740","article-title":"Promising therapeutic drug delivery systems for glaucoma: a comprehensive review","volume":"12","author":"Singh","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/ph16091241","article-title":"Suprachoroidal injection: a novel approach for targeted drug delivery","volume":"16","author":"Wu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","article-title":"Phase 3, randomized, 20-month study of the efficacy and safety of Bimatoprost implant in patients with open-angle Glaucoma and ocular hypertension (ARTEMIS 2)","volume":"81","author":"Bacharach","year":"2021","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","article-title":"Efficacy and safety of the Travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle Glaucoma or ocular hypertension","volume":"84","author":"Berdahl","year":"2024","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17469899.2022.2114456","article-title":"Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis","volume":"17","author":"Thomas","year":"2022","journal-title":"Expert Rev Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jconrel.2022.05.061","article-title":"Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions","volume":"349","author":"Kansara","year":"2022","journal-title":"J Control Release"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.drudis.2019.03.027","article-title":"Targeting drug delivery within the suprachoroidal space","volume":"24","author":"Jung","year":"2019","journal-title":"Drug Discov Today"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J Control Release"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2001908","DOI":"10.1002\/advs.202001908","article-title":"Drug-free, nonsurgical reduction of intraocular pressure for four months after suprachoroidal injection of hyaluronic acid hydrogel","volume":"8","author":"Chae","year":"2021","journal-title":"Adv Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/nn4046024","article-title":"Sustained drug release in nanomedicine: a long-acting Nanocarrier-based formulation for Glaucoma","volume":"8","author":"Natarajan","year":"2014","journal-title":"ACS Nano"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e24513","DOI":"10.1371\/journal.pone.0024513","article-title":"Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye","volume":"6","author":"Natarajan","year":"2011","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/IJN.S25468","article-title":"Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye","volume":"123","author":"Venkatraman","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13346-014-0196-9","article-title":"Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops","volume":"4","author":"Wong","year":"2014","journal-title":"Drug Deliv Transl Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13346-021-00912-x","article-title":"Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I\/II clinical trial","volume":"12","author":"Wong","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2020.11.053","article-title":"In vivo fate of liposomes after subconjunctival ocular delivery","volume":"329","author":"Chaw","year":"2021","journal-title":"J Control Release"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.exer.2003.07.002","article-title":"Goldmann\u2019s equation and clinical measures of aqueous dynamics","volume":"78","author":"Brubaker","year":"2004","journal-title":"Exp Eye Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1515\/jbcpp-2018-0002","article-title":"Rabbits and men: relating their ages","volume":"29","author":"Dutta","year":"2018","journal-title":"J Basic Clin Physiol Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1776626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:05Z","timestamp":1772775005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1776626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1776626"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1776626","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1776626"}}